Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sodium phosphate laxative warnings, use limits to be subject of "feedback" meeting.

This article was originally published in The Tan Sheet

Executive Summary

SODIUM PHOSPHATE LAXATIVES NEW WARNINGS, USE LIMITS for both oral and rectal products are expected to be discussed at an OTC "feedback" meeting at FDA tentatively scheduled for July 15. In response to objections by the laxative manufacturers Nutramax and C.B. Fleet, the agency has agreed to a meeting on the new requirements, which were part of a May 21 final rule on sodium phosphate laxatives ("The Tan Sheet" May 25, p. 9). Among the companies' objections is that the warnings and directions for both types of products required by the rule were not previously proposed by the agency and therefore not subject to prior notice and comment as required by the Administrative Procedures Act.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel